Literature DB >> 8912405

Effect of a thyrotrophin-releasing hormone analogue, RX77368, on AMPA-induced septal-hippocampal lesioned rats in an operant delayed non-matching to position test.

T M Ballard1, A J Hunter, G W Bennett.   

Abstract

The aim of the present study was to determine the effect of a thyrotrophin-releasing hormone (TRH) analogue, RX77368, on performance of a working memory test, using a delayed non-matching to position (DNMTP) procedure, in (RS)-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-induced septal-hippocampal lesioned rats. Following a post-surgery recovery period, pretrained rats were tested once daily on DNMTP, 30 min post-administration of RX77368 (1.0 mg kg-1, i.p.) or saline. AMPA-induced lesions significantly reduced percent correct responses during the second week of testing. Comparison of percent correct responses between days 1 and 13 of testing showed that sham rats significantly improved DNMTP performance, whereas lesioned rats did not. RX77368 significantly reduced general locomotor activity in sham rats in activity boxes, but did not disrupt non-mnemonic measures, such as locomotion and motivation, in the DNMTP test. RX77368 increased percent correct responses in AMPA-lesioned rats on days 8-10 and 11-13. There was also a significant improvement in percent correct responses achieved between day 1 and 13 in RX77368-treated lesioned and sham rats. These results showed that: (i) septal-hippocampal lesioned rats did not improve over the testing period; and (ii) on test days when a significant impairment was present, RX77368 partially improved DNMTP performance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8912405

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  50 in total

1.  Medial septal lesions disrupt spatial mapping ability in rats.

Authors:  J E Kelsey; B A Landry
Journal:  Behav Neurosci       Date:  1988-04       Impact factor: 1.912

2.  Place navigation in rats is impaired by lesions of medial septum and diagonal band but not nucleus basalis magnocellularis.

Authors:  J J Hagan; J D Salamone; J Simpson; S D Iversen; R G Morris
Journal:  Behav Brain Res       Date:  1988-01       Impact factor: 3.332

3.  TRH-catecholamine interactions in brain and spinal cord.

Authors:  G W Bennett; C A Marsden; K C Fone; J V Johnson; D J Heal
Journal:  Ann N Y Acad Sci       Date:  1989       Impact factor: 5.691

4.  Comparative effects of cholinergic drugs and lesions of nucleus basalis or fimbria-fornix on delayed matching in rats.

Authors:  S B Dunnett
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

5.  Selective loss of central cholinergic neurons in Alzheimer's disease.

Authors:  P Davies; A J Maloney
Journal:  Lancet       Date:  1976-12-25       Impact factor: 79.321

6.  Necropsy evidence of central cholinergic deficits in senile dementia.

Authors:  E K Perry; R H Perry; G Blessed; B E Tomlinson
Journal:  Lancet       Date:  1977-01-22       Impact factor: 79.321

7.  Localization of thyrotropin-releasing hormone (TRH) receptors in the septal nucleus of the rat brain.

Authors:  S M Simasko; A Horita
Journal:  Brain Res       Date:  1984-04-02       Impact factor: 3.252

8.  NS-3, a TRH analog, reverses repeated ECS-induced deficits in water maze performance in the rat.

Authors:  A Khan; H Lai; Y Ukai; M H Mirolo
Journal:  Pharmacol Biochem Behav       Date:  1994-03       Impact factor: 3.533

9.  Lesions of the medial septum which produce deficits in working/spatial memory do not impair long-term potentiation in the CA3 region of the rat hippocampus in vivo.

Authors:  K J Feasey-Truger; B H Li; G ten Bruggencate
Journal:  Brain Res       Date:  1992-09-25       Impact factor: 3.252

10.  Thyrotropin-releasing hormone (TRH) and its analog (DN-1417): interaction with pentobarbital in choline uptake and acetylcholine synthesis of rat brain slices.

Authors:  S Narumi; Y Nagai; M Miyamoto; Y Nagawa
Journal:  Life Sci       Date:  1983-04-04       Impact factor: 5.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.